Clinical trials have shown that polyethylene glycol-conjugated G-CSF prevents neutropenia and febrile neutropenia in patients receiving oxaliplatin-containing chemotherapy (Kitagawa et al., 2020; Macaire et al., 2020). The gene discussed is CSF3; the disease is Decreased total neutrophil count.